Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore

by IANS |

Bengaluru, Oct 22 (IANS) Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth was up by 10 per cent at Rs 1,945 crore, primarily driven by good performance of the Research Services and Biosimilars business segments.

Announcing consolidated financial results for the second quarter ending September 30, 2021, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said the factors responsible for the profit reported a growth of 17 per cent and 10 per cent respectively.

"EBITDA at Rs 551 crore was up by 35 per cent and PBT (before exceptional items) at Rs 276 crore went up by 27 per cent. The exceptional item relates to modification of the optionally convertible debentures of a PE investment in Biocon Biologics and reversal of SEIS claims relating to a prior period. Net Profit for Q2FY22, before such exceptional items, was Rs 188 crore, up 11 per cent. Our Core EBITDA margins for the quarter were at a healthy 33 per cent," she explained.

Kiran claimed: "Biocon Biologics made strategic moves this quarter which will drive future growth of our Biosimilars business and deliver long-term value for our shareholders. The US FDA's approval of Semglee as the first interchangeable biosimilar product under the 351(k) regulatory pathway, is a historic milestone for both Biocon and Viatris, and will enable us to expand patient access to our Insulin Glargine," she said.

The Executive Chairperson stated, this has led to Semglee's inclusion as a preferred Insulin Glargine brand on the National Preferred Formulary of Express Scripts, a leading Pharmacy Benefit Manager (PBM). We expect the formulary coverage to begin in January 2022 and believe Semglee has the potential to bring significant cost savings for patients, employers and PBMs," she added.

"The quarter also marked Biocon Biologics' strategic entry into vaccines and the infectious diseases segment through key partnerships with Serum Institute Life Sciences and Adagio Therapeutics," she underlined.

Kiran said: "With the waning pandemic and improvements in supply chain conditions, I believe all three business segments, Generics, Biosimilars and Research Services, are well positioned for sustained growth in H2FY22."

Latest News
FIR against Omicron-positive S African national for fleeing Bengaluru Tue, Dec 07, 2021, 08:11 PM
Amicus Curiae to look into mosquito menace in Delhi Tue, Dec 07, 2021, 08:08 PM
Sand mafia in Punjab worth Rs 20,000 crore: Kejriwal Tue, Dec 07, 2021, 08:05 PM
Geospatial sector set to grow almost 14%, experts call for forward looking policy Tue, Dec 07, 2021, 08:03 PM
India is not one economy but aggregate of economies: Meenakshi Lekhi Tue, Dec 07, 2021, 08:00 PM
Verdict in 29 days: Death penalty to rape and murder convict Tue, Dec 07, 2021, 07:58 PM
Drugs worth over Rs 508 cr seized in Manipur, one Myanmarese held Tue, Dec 07, 2021, 07:56 PM
Action initiated to set up genome sequencing labs in Karnataka: Bommai Tue, Dec 07, 2021, 07:53 PM
Congress seeks probe into illegal construction at UNESCO-endorsed church Tue, Dec 07, 2021, 07:48 PM
Lawyer files complaint against JNUSU over Babri Masjid protest march Tue, Dec 07, 2021, 07:46 PM
KMC polls: No need for central forces, SEC tells Raj Bhawan Tue, Dec 07, 2021, 07:43 PM
Accused in fake certificate racket arrested in J&K Tue, Dec 07, 2021, 07:41 PM
Amarinder lashes out Congress over Maken's appointment Tue, Dec 07, 2021, 07:39 PM
Magician drives vehicle blindfolded to 'open Vijayan's eyes' Tue, Dec 07, 2021, 07:37 PM
Omicron positive doctor in Karnataka again tests Covid positive Tue, Dec 07, 2021, 07:35 PM